Home › Epidermolysis Bullosa › NCT06834035

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Who can join

Ages 6 and older · All sexes

Inclusion Criteria:

1. Diagnosis of generalized Recessive dystrophic epidermolysis bullosa (RDEB) demonstrated by COL7A1 mutations.
2. Diagnosis of EBA demonstrated by the presence of levels of serum C7 antibodies above the normal ELISA range
3. Baseline skin blistering greater than 5% total body surface area
4. 1 wound at least 20 cm\^2 able to be entirely treated with Vyjuvek weekly
5. 1 wound at least 20 cm\^2 that has never been treated with Vyjuvek
6. Ongoing VYJUVEK treatment.

Exclusion Criteria:

1. History of thrombotic event(s)
2. History of cardiac failure
3. History of renal failure
4. IgA deficiency

About the study

The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum.

Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.

What is being tested

• Immunoglobulin G (biological)

Sponsor: M. Peter Marinkovich · Participants: 8 · Started: Aug 4, 2025

Contact the study team

• Kunju Clinical Research Coordinator, PhD · Phone: 650-721-4902

Official record on ClinicalTrials.gov — NCT06834035

Locations in the U.S.

Conditions

• Epidermolysis Bullosa
• Epidermolysis Bullosa Dystrophica

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.